AcuCort AB (ACUC) Q4 2024 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Acucort Ab.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:05.197 Hello and a warm welcome to Investor Update, today with Accocort's 00:00:05.197 -- 00:00:09.762 annual report, which will be presented by CEO Jonas Jönmark. 00:00:09.762 -- 00:00:14.207 Hi Jonas. Nice to be here, nice to be able to talk about Accocort. 00:00:14.207 -- 00:00:19.853 Yes, we look forward to that. And as always when we broadcast live, you can interact 00:00:19.853 -- 00:00:24.578 with the company management, and that makes it easier by writing your questions in the 00:00:24.578 -- 00:00:29.445 chat field. We will handle those questions at the end of the presentation, but it might 00:00:29.445 -- 00:00:33.970 be good to get them in as early as possible so we can present them before the broadcast 00:00:33.970 -- 00:00:36.834 is over. And with that, Jonas, 00:00:36.834 -- 00:00:39.077 I'll hand it over to you. The stage is yours. 00:00:39.077 -- 00:00:42.442 Thank you very much. I thought 00:00:42.442 -- 00:00:47.648 we would talk about the company during 2024, and we will take a deep dive into the 00:00:47.648 -- 00:00:49.931 last quarter of 2024. 00:00:49.931 -- 00:00:53.316 But we will also talk about what's coming 00:00:53.316 -- 00:00:55.356 up. commercialization, 00:00:56.141 -- 00:01:01.370 the potential of the product and so on. But let's first look at 00:01:01.370 -- 00:01:06.879 what Accocort does. We have a very smart product called Secmellit, 00:01:06.879 -- 00:01:11.227 which improves the lives of people with severe allergies. 00:01:11.227 -- 00:01:16.412 The product is a very smart mouth film. 00:01:16.694 -- 00:01:21.881 If we look at the fourth quarter of 2024, there has been no turnover during the period 00:01:21.881 -- 00:01:27.147 as expected. The result after the tax went up to about minus 7.5 00:01:27...